Plant Trees SF Events 2005 Archive: 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Event

 

Enemy of the state

Ignacio Chapela was once the cream of the scientific core at Berkeley 
university, California. Now he is reviled. He tells John Vidal how US 
academic institutions are being 'bought' by biotechnology firms that are 
backed by the government

Wednesday January 19, 2005
<http://www.guardian.co.uk>http://society.guardian.co.uk/societyguardian/story/0,,1392979,00.html

Eight years ago, Ignacio Chapela was a rising star of American academe; 
an assistant professor of microbial ecology at Berkeley university in 
California, sitting on high-level scientific committees and with the 
seemingly certain prospect of career advancement and a well-paid job for 
life.

Chapela, a mushroom expert, had no problem with biotech crops. Indeed, 
he had worked for several years with the Swiss company Sandoz, which 
later became GM giant Novartis.

But now Chapela has lost his job, is unemployable in any other 
top-ranking US university, and admits he is "extremely biased" against 
the industry. He is furious with the highest levels of Berkeley, 
believing that it and other major academic institutions have been 
"bought". The biotech industry, he says, exerts a vice-like grip on the 
US government and Chapela is preparing to spend years in the courts.

What turned this once mild Mexican scientist into one of the world's 
leading defenders of academic freedom and one of the loudest critics of 
biotech? Chapela, in Britain to address the Soil Association annual 
meeting in Newcastle, says he gained "knowledge". Specifically, he 
questioned a "donation" to Berkeley by a GM giant and then discovered 
that GM maize was seriously polluting Mexico. In so doing, he has made 
powerful enemies.

There were several radicalisation points, he says. "One was when I was 
asked to be part of a National Academy of Science [equivalent of a Royal 
Society] committee supposedly looking at the scientific foundation for 
the regulatory status of GM. We were being asked, I realised, to give a 
scientific excuse for deregulation.

"'I have two questions,' I said. The first was about substantial 
equivalence [when a new food or food component is found to be 
substantially equivalent to an existing food or food component]; the 
second was whether we could review what happens if we lost control of 
the GM through, say, cross-pollination. For both, we had a big thumb's 
down from the top. We were told 'thou shalt not ask that'. A reasonable 
scientist should always react with suspicion to suppression."

That was the point, he says, when he decided to go to Mexico and 
research the potential spread of GM maize, which was flooding over the 
border. He sent a colleague, who found widespread GM contamination, with 
grave implications for biodiversity. After rigorous testing, they 
compiled a paper for the British science journal Nature, but even before 
publication a powerful campaign was mounted against them, involving a 
Washington PR firm, industry-friendly scientists in Europe and the US, 
and the Mexican government. Six months after publication, Nature 
effectively withdrew its support for his article. It was accused of 
being lobbied by the friends of the industry, but denied it.

At the same time, Berkeley tried to stop Chapela getting his tenure (a 
job for life). Despite overwhelming support by his academic peers, up to 
and including the dean, he was denied it and he has now given his last 
lecture. "The support was extraordinary," he says. "At least 200 people, 
perhaps more, demonstrated for me."

In itself, the Mexican research was probably not enough to lose him his 
job. But Chapela has "form". In 1997, when chair of a faculty committee, 
he questioned the ethics of an industry offer to Berkeley from his old 
company, and made many enemies.

"One of the reasons I needed to be kicked out is that I opposed a $50m 
[£27m] donation to the university by Novartis," he says. In return, the 
company was to fund a third of all the work in the department and get a 
first look at all the research papers. "I stood against it and dragged 
the university all the way to the senate of California. In the end, the 
donation [was reduced] to $25m [£13m].

"They hate me," he says, but he cannot say exactly who because the 
individuals who insisted he was fired "are anonymous, not accountable, 
hold enormous power and act as a corporate body. One of these power 
sources is unquestionably the biotech industry".

Chapela reckons that the industry has received more than $200bn (£107bn) 
of US public money over the years and should be bankrupt by now. "It 
should have died three years ago," he insists. "Why is the industry 
still alive? It's bleeding like crazy. The answer is that the industry 
is in the national interests of the US. The state department handles it. 
It's not about economic value but government [strategy]. It is built 
into the rightwing agenda of the US at executive branch level."

But Chapela is baffled by the British government's support for 
agricultural biotech. "I can tell what is in it for the US. I can 
understand Bush [senior] and Dan Quayle thinking [in the 1990s] that it 
looked promising and taking the risk, but I have absolutely no idea what 
you guys [the British] are in it for."

He says the vast amounts of money put into US universities by biotech 
firms is fundamentally altering the way biology is approached. No one, 
Chapela says, wants to pursue the kind of research he undertook in 
Mexico because they are afraid of the consequences. "But there is a 
growing understanding that universities have been hijacked and the whole 
science establishment has become vested in this project. Professors are 
now becoming entrepreneurs and students are becoming employees. Now you 
get asked how many patents you hold when you go for a job."

Meanwhile, Chapela is preparing a court case against the university that 
he hopes will expose its relationship with biotech and other 
unaccountable industrial funders. He believes that the biotech industry 
wants it: "The industry needs to show the pain in standing up to it. It 
wants a case to show its chilling influence. We have no option but to 
keep challenging it."

· Letters on any issue covered on the environment pages can be sent to 
Society Guardian, 119 Farringdon Road, London EC1R 3ER or fax 020-7713 
4154 or email society@guardian.co.uk 

*

For updates and info, contact scott at planttrees dot org.